TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MannKind ( (MNKD) ) has provided an update.
On November 10, 2025, MannKind Corporation announced the discontinuation of its Phase 3 clinical trial for MNKD-101, a nebulized inhalation suspension of clofazimine for treating refractory nontuberculous mycobacterial lung disease. This decision followed the analysis of data from the first 46 participants, which showed no evidence of sputum culture conversion, leading to concerns about achieving the study’s primary endpoint. The data safety monitoring board agreed with the decision due to futility, although no safety issues were found. MannKind plans to investigate the outcome to guide the development of MNKD-102, a dry powder formulation of clofazimine advancing towards Phase 1.
The most recent analyst rating on (MNKD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on MannKind stock, see the MNKD Stock Forecast page.
Spark’s Take on MNKD Stock
According to Spark, TipRanks’ AI Analyst, MNKD is a Neutral.
MannKind’s overall stock score reflects a mix of strengths and challenges. The most significant factor is the company’s strong revenue growth and strategic acquisitions, as highlighted in the earnings call. Technical analysis supports a positive outlook with bullish momentum. However, the high P/E ratio and balance sheet concerns, including negative equity, weigh on the score.
To see Spark’s full report on MNKD stock, click here.
More about MannKind
MannKind Corporation operates in the biopharmaceutical industry, focusing on the development and commercialization of therapeutic products for diseases such as diabetes and pulmonary conditions. The company is known for its innovative drug delivery systems, including inhalation technologies.
Average Trading Volume: 4,744,718
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.73B
For detailed information about MNKD stock, go to TipRanks’ Stock Analysis page.